APB-C001

N/A

Report date: 2025/01/26 18:45:44

Base Information

Drug NameAPB-C001

Drug Alias Nameanti-L1CAM CAR T-cell therapy (Apitbio)anti-CD171 CAR T-cell therapy (Apitbio)APB-C001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionNeural cell adhesion molecule L1 modulators

TargetsNeural cell adhesion molecule L1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesApitbio Inc

China Registration ClassN/A

Develop Information

Active CompaniesApitbio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A